measles (rubeola) vaccine (Discontinued)

  • Print
Brand and Other Names:Attenuvax

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

vaccine

  • lyophilized supplied with diluent
more...

Measles Vaccination

0.5 mL SC

Additional Information

Up-to-date vaccination schedules available at www.cdc.gov/nip/publications

Other Indications & Uses

(MMR preferred)

Dosage Forms & Strengths

vaccine

  • lyophilized supplied with diluent
more...

Measles Vaccination

<12 months old: 0.5 mL SC; give additional dose between 12-15 months old

>12 months old: 0.5 mL SC

Revaccination with MMR-II recommended before elementary school entry

Next:

Interactions

Interaction Checker

and measles (rubeola) vaccine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Fever (5-15%)

            1-10%

            Rash (5%)

            Frequency Not Defined

            Pain at site

            Syncope

            Headache

            Dizziness

            Malaise

            Irritability

            Encephalitis

            Guillain-Barre synd

            Subacute sclerosing panencephalitis (rare)

            Seizure

            Thrombocytopenia

            Stevens-Johnson syndrome

            Previous
            Next:

            Warnings

            Contraindications

            Pregnancy

            Hypersensitivity to eggs, neomycin, gelatin

            Immunosuppression secondary to CA, AIDS, therapy, etc

            Concurrent Immune Globulins or immunosuppressive drugs

            Blood dyscrasias, hematologic cancers

            Congenital immunodeficiency

            Febrile respiratory illness or other active febrile infection

            • minor infections can be exempted

            Cautions

            Trivalent MMR is preferred agent

            Those born prior to 1957 are generally considered immune

            Avoid pregnancy for 3 mth after vaccination

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known if excreted in breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Duration: Unknown

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Pharmacogenomics

            HLA-B7, HLA-B51, HLA-DRB1*13, and HLADQA1*01 is associated with a measles vaccine response

            Homozygosity at HLA-B, HLA-DR, and HLA-DQA1 has been associated with a measles vaccine nonresponse

            Mechanism of Action

            Live, attenuated measles virus stimulates active immunity

            Previous
            Next:

            Images

            Previous
            Next: